Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Publication|Articles|February 2, 2024
- Pharmaceutical Technology, February 2024
- Volume 48
- Issue 2
- Pages: 10
Dissolution Testing Software
Author(s)Pharmaceutical Technology Editors
Distek’s software update for the Opt-Diss–In-Situ Fiber Optic UV System for Dissolution Testing, Version 3.20, introduces enhancements designed to streamline the dissolution testing process and expand the system’s capabilities.
The release of Distek’s software update for the Opt-Diss–In-Situ Fiber Optic UV System for Dissolution Testing, Version 3.20, introduces enhancements designed to streamline the dissolution testing process and expand the system’s capabilities. Among the key updates in Version 3.20 are an integrated media addition, a dosage weight correction feature, and run automation for complete systems.
The process of analyzing tests that employ changing or adding additional media during testing has been simplified and automated, and automatically pauses measurements for media changes, which generates a consolidated report with visual demarcation of media change instances.
Recording individual dosage weights are now allowed, enabling the correction of % dissolved/concentration values for each dosage form. Non-uniform dosage forms particularly benefit from this feature.
Complete run automation is now possible for Distek systems equipped with a dosage auto-dropper option. This culminates in the automatic generation, storage, and optional printing of final reports.
Articles in this issue
over 2 years ago
European Medicines Agency Viewpointover 2 years ago
Emerging Therapies Drive Analytical Advancementsover 2 years ago
QbD for Small-Molecule Continuous Process Developmentover 2 years ago
Compounding Overview: Primary Considerations for the Workplaceover 2 years ago
Analyzing Exabytesover 2 years ago
Addressing PK/PD Study Design Early in Developmentover 2 years ago
MHRA’s New International Recognition Procedureover 2 years ago
On the Up and Upover 2 years ago
J.P. Morgan Losing WeightRelated to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.